Advanced ECG biomarkers from iCardiac Technologies provide hope for pharma development pipelines

The mood in the pharmaceutical development world is not good. Fewer new products being approved despite rising R&D expenditures, and many marketed products are under threat because of safety and efficacy concerns.

There are several reasons for the dearth of new products and rising cost of pharmaceutical development. One major challenge is the FDA’s requirement for so-called Thorough QT (TQT) studies to determine whether a drug may induce prolongation of the QT interval on ECGs in the healthy volunteers who comprise the Phase I study population.

As Alexandra (Sasha) Latypova and Anthony Fossa from iCardiac Technologies, Inc. –a company whose board I serve on– write in the current issue of Drug Discovery & Development:

The purpose of the TQT study, as stated by regulators, is to decide whether more extensive ECG monitoring is necessary in subsequent development… In reality, however, a positive TQT study or even QT prolongation detected in preclinical studies most often leads to termination of the drug development program, as both sponsors and regulators have become increasingly risk-averse in the wake of the recent, high-profile, market withdrawals of several blockbuster drugs.

Prolonged QT as a biomarker has been widely-criticized for its high rate of false-positives and false-negatives. Consider the case of cisapride (Propulsid), a drug for gastrointestinal motility disorder. When the drug was evaluated for cardiotoxicity in humans using FDA-required testing, cisapride exhibited a small prolongation of the QT interval and consequently was considered safe for marketing. Once on the market, cisapride was associated with numerous arrhythmic events, including 341 cases of life-threatening cardiac arrhythmias with 15 sudden-cardiac arrests over a period of six years.

[T]he litigation costs of false-negatives can be astronomical—class action suits and legal fees alone for cisapride exceeded $100 million. The conservative regulatory guidance has now dramatically reduced the probability of a false-negative QT study. However, false-positive QT studies produce an enormous “silent” burden on society. A false-positive QT study may cause an unnecessary termination or adverse labeling for an inherently safe drug and thus lead to lack of access to new medicines for patients that need them while at the same time contributing to the skyrocketing costs of new drugs. Some examples of false-positive QT drugs that did make it to market include moxifloxacin (an antibiotic), amiodarone (an anti-arrhythmic), tamoxifen (anti-neoplastic) and ziprasidone (an antipsychotic). All are associated with significant QT prolongation but do not have pronounced arrhythmogenic properties at therapeutic doses.

iCardiac is developing advanced cardiac safety biomarkers in order to overcome the limitations of TQT. Success will increase the chance that the next moxifloxacin, amiodarone, tamoxifen and ziprasidone make it to market, while protecting us from the next cisapride. I look forward to doing my part to help the company succeed.

I interviewed iCardiac’s Chairman and CEO, Mikael Totterman last year.

Accept credit card today
Reading credit reports
Log home insurance
Consolidation debt loan mortgage second
Debt consolidation information
Credit card applications online
Creditreports
Best rates on life insurance
Instant approval cards
Credit repair forum
Improving credit scores
Texas health insurance provider
Long term care insurance business
Debt consolidation advice blogs
Online credit scores
Long term care insurance price
Student loan servicing center
Instant auto loan
Refinance your california home mortgage
Group disability income insurance
Health insurance association guide to long term care
Credit score definition
Best credit card uk
Debt consolidation non profit organization
Read credit reports
Low fee payday loan
Credit card processing rates
Average national credit score
Insurance swinger life style
On my credit report
Credit reporting agencies
Tenant credit reports
California home equity loans
Small business health insurance quotes
Debt settlement in
Good credit score
Instant credit reports
Insurance life leads
Transunion credit reports
Long term care insurance policy
Canadian credit card application
Credit reports for landlords
Credit card application forms
Health insurance for senior citizen
Stop credit card offer
Debt consolidation service
Debt it settlement yourself
Direct loans student loans
Credit repair tips letters
Credit reporting agency
Credit card company abuse
Refinance st charles
Low term life insurance rate
Term life insurance company
Disney chase credit card
Health insurance rate
Emerge credit card services
Extended auto warranty california
Credit card application canada
Guaranteed issue life insurance
Credit report score
Auto loans bad credit online
Auto loan interest rates
Excellent credit score number
Credit card apr 0
Small group health insurance
Counseling credit card debt
Insurance discovery health sexual secrets
Elan credit card services
Up credit reports
Loan rates home equity loans
Term life insurance protection
Commercial loan
Gas credit card application
Free instant credit score
Citibank credit card application
Free home owner insurance quote

One thought on “Advanced ECG biomarkers from iCardiac Technologies provide hope for pharma development pipelines

  1. Pingback: What icardiac | TexasAnalytical

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s